SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
North view of the White House, with waving flag and cloudy sky, on a reflective surface that could be glass or water. 3D Illustration
Government
WHO Withdrawal, CGT Access, IRA: Trump’s Initial Policies Raise Questions for Biopharma
At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, President Trump issued multiple executive orders that concern the industry.
January 22, 2025
 · 
5 min read
 · 
Annalee Armstrong
Business people shaking hand in China.
ADCs
ArriVent Joins Chinese Licensing Trend With Potential $1.2B+ ADC Deal with Lepu
With an eye toward advancing a novel antibody-drug conjugate for gastrointestinal cancers, ArriVent is the latest biopharma player to ink a deal with a Chinese biotech.
January 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Correct decision chosing - confused man character standing on the crossroads and looking at signpost with three different directions - conceptual vector illustration
Deals
Almost 5 Years into $5B Galapagos Partnership, Gilead Execs Start Over With New Spinoff
Five years ago, Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at the original signing.
January 22, 2025
 · 
5 min read
 · 
Annalee Armstrong
Johnson & Johnson's business center in Switzerland
Depression
J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval
Spravato’s monotherapy nod on Tuesday comes after a series of setbacks in the depression space.
January 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Large yellow signboard on metal frame with the word IPO. Clear sky in the background. Concept of share trading on stock market, capital investment, currency exchange
IPO
Chinese Biotech Ascentage Aims For $134M IPO
Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia and for certain types of chronic myeloid leukemia.
January 22, 2025
 · 
2 min read
 · 
Tristan Manalac
FDA sign in front of its building in Maryland
Regulatory
FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets
The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a third-party provider while releasing Amylyx’s investigational ALS therapy from a previous pause.
January 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Business
Trump Takes Over, Wegovy Still Trails Zepbound and BioSpace Recaps JPM
Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM and her talks with Biogen, Gilead, Novavax and more; Wegovy’s higher dose induces more weight loss; AstraZeneca and Daiichi Sankyo’s Dato-DXd scores its first FDA approval.
January 22, 2025
 · 
1 min read
 · 
Heather McKenzie
Man preparing his GLP-1 injection
GLP-1
The Good, the Bad and the Ugly of GLP-1s: Study
Computational research conducted by scientists from Washington University in St. Louis shows that GLP-1 agonists can have mental and cognitive health benefits but may also harm the kidneys and pancreas.
January 21, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Pictured: Facade of Moderna's building in Massachusetts
Vaccines
Moderna Nabs Another $590M from HHS for mRNA-Based Bird Flu Vaccines
The funding, which follows the $176 million the government awarded Moderna in June 2024, aims to get mRNA vaccines ready before bird flu strains currently circulating in the wild and on farms can potentially cause human outbreaks.
January 21, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS